Navigation Links
Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer

EXTON, Pa., Oct. 2 /PRNewswire/ -- Othera Pharmaceuticals, Inc., a specialty pharmaceuticals company focused on novel, patient-administered products for ophthalmology, oncology, and inflammatory disease, has announced the appointment of Frederick R. Rickles, MD, FACP, as Chief Scientific Officer effective immediately. In this position, Dr. Rickles will lead the development, integration and execution of Othera's research and clinical development programs.

"We are delighted to welcome Dr. Rickles to the Othera team," said David Joseph, Chairman and CEO of Othera Pharmaceuticals, Inc. "His broad expertise in oncology, hematology (thrombosis), and pharmacology will serve Othera well as we pursue our goal of becoming a leading specialty pharmaceutical company. Othera's business strategy requires an important focus on product diversification and target selection, and, thus, we will benefit from his extensive background and expertise."

Commenting on his new position, Rickles said, "This is an outstanding opportunity to join a specialty pharmaceutical company at a very important strategic stage of the organization. I believe that Othera's novel molecules and extensive intellectual property gives us the flexibility to build our future portfolio and create a broad growth platform, and I am delighted to have a key role in that effort."

Rickles, a 37-year veteran of the Medical Community, presently serves as a Fellow in the Center for Science and Technology, Healthcare Division of Noblis, a non-profit organization that works in the public interest. Among other important healthcare projects, Noblis helped the Centers for Medicare and Medicaid Services (CMS) implement Medicare Part D. Dr. Rickles has been working on a number of healthcare policy issues for Noblis, including pharmacovigilance, with a consortium of public and private stakeholders. Additionally, he has served as Associate VP/Health Research at The George Washington University (GWU) and was the CEO and Executive Director of the Federation of American Societies for Experimental Biology (FASEB), a coalition of 21 leading life science research organizations. He also served as a scientific advisor for multiple leading pharmaceutical and private sector companies and such as Pfizer and Caremark, respectively.

Rickles is a graduate of the University of Illinois College of Medicine and trained in internal medicine and hematology at the University of Rochester/Strong Memorial Hospital. He will continue to serve as a Professor of Medicine in the Division of Hematology-Oncology, Department of Medicine at GWU. He will also maintain his position as a teaching attending physician at the GWU Hospital in Washington, DC. Rickles will also continue to serve as member of multiple editorial boards, medical association committees, and scientific advisory boards.

About Othera Pharmaceuticals

Founded in 2002, Othera Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing novel, patient-administered products for ophthalmology, oncology, and inflammatory diseases.

Othera's most advanced product is currently in Phase 2 clinical trials for the treatment of major age-related macular degeneration (AMD). OT-551 is a novel small molecule that inhibits oxidative stress and disease-induced inflammatory responses that contribute to loss of vision in AMD patients. "OT-551 is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye," said David S. Joseph, chairman and CEO of Othera Pharmaceuticals. "We are very encouraged by preclinical research results demonstrating that OT-551 may be the first drug treatment for both the dry and wet form of age-related macular degeneration (AMD). Two Phase 2 trials of OT-551 in AMD patients are currently underway with initial results expected in 2008."

In addition to its lead compound, OT-551, Othera is also developing OT-730 as a novel improved beta-blocker for treatment of glaucoma. OT-730 is designed to have excellent beta-blocking activity in the eye, yet easily break down into inert components upon entry into the bloodstream. Today's marketed beta-blockers as a class are the most widely-prescribed drugs by volume for glaucoma, but suffer from the potential danger of systemic side effects. Initial preclinical studies support the concept that OT-730 could overcome the systemic side effect problem. An IND filing is planned for 2008.

Othera's product pipeline also includes orally-acting, small molecule analogues of OT-551. OT-304 has been identified as the lead candidate in this series and has demonstrated activity in preclinical models of cell-mediated thrombosis in cancer and inflammatory diseases. Completion of preclinical development supporting the use of OT-304 in the treatment and/or prevention of thrombosis in cancer and inflammatory diseases is expected later this year. The appointment of Dr. Rickles as CSO will enhance Othera's existing development capabilities and expertise as he is one of the most recognized experts in cancer and thrombosis in the world.

For information please visit Othera's website at

SOURCE Othera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. TomoTherapy opens technical training center
3. TomoTherapy raises $223 million in IPO
4. TomoTherapy revises IPO money target
5. Hospital named for Madame Curie installs TomoTherapy system
6. TomoTherapy files registration statement for IPO
7. TomoTherapy to sell medical devices in India
8. TomoTherapy sees sustained market advantage
9. TomoTherapys 100th radiology system reaches public sector
10. TomoTherapy extends reach to Germany
11. Cash-rich TomoTherapy has no plans for IPO
Post Your Comments:
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)... 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual ... 11:00 a.m. Israel time, at the law offices ... Street, 36 th Floor, Tel Aviv, Israel . ... and Izhak Tamir to the Board of Directors; , ... , approval of an amendment to certain terms of options granted ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Inc., on being named to Deloitte's 2015 Technology Fast 500 list of the ... manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic tooth ...
Breaking Biology Technology:
(Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
Breaking Biology News(10 mins):